



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : C12Q 1/02, 1/70, C09H 1/04 A01N 25/26, 25/28, A61K 35/14 A61K 37/04, 37/22, G01N 33/48 G01N 33/53, 33/92, 33/532 G01N 33/533, 33/534, 33/537 G01N 33/555, 33/566, 33/567</p>	A1	<p>(11) International Publication Number: WO 90/14435</p> <p>(43) International Publication Date: 29 November 1990 (29.11.90)</p>
<p>(21) International Application Number: PCT/US90/02341</p> <p>(22) International Filing Date: 27 April 1990 (27.04.90)</p> <p>(30) Priority data: 345,436 1 May 1989 (01.05.89) US</p> <p>(71) Applicant: ZYNAXIS TECHNOLOGIES, INC. [US/US]; 371 Phoenixville Pike, Malvern, PA 19355 (US).</p> <p>(72) Inventors: MELNICOFF, Meryle, J. ; 220 North Woodstock Drive, Cherry Hill, NJ 08034 (US). MUIRHEAD, Katharine, A. ; 226 Caswallen Drive, West Chester, PA 19380 (US). HORAN, Paul, K. ; 30 Heron Hill Drive, Downingtown, PA 19335 (US).</p>	<p>(74) Agents: HAGAN, Patrick, J. et al. ; Dann, Dorfman, Herrell and Skillman, One Meridian Plaza - Suite 900, 1414 South Penn Square, Philadelphia, PA 19102-2440 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: METHODS, REAGENTS AND TEST KITS FOR DETERMINATION OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES</p> <p>(57) Abstract</p> <p>Analytes, having a characteristic determinant that selectively interacts with a specific binding substance, are determined by coupling a reporter substance to the analyte, or to the specific binding substance, causing complex formation between the analyte and the specific binding substance in a test medium, separating the complexes thus formed from the test medium, and determining the presence or quantity of the analyte of interest by detecting the occurrence of the reporter substance in the complexes or the separated test medium. The determination is preferably performed on biomembrane-containing entities, such as cell subpopulations and/or subsets thereof, the reporter substance being stably associated with the lipid component of the biomembrane. Reagents and test kits are disclosed for performing the analyte determination.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

- 1 -
METHODS, REAGENTS AND TEST KITS FOR DETERMINATION
OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES

This application is a continuation-in-part of co-pending U.S. patent application Serial No. 189,192, filed May 2, 1988 and entitled "Compounds, Compositions and Methods for Binding Bio-Affecting
5 Substances to Surface Membranes".

Field of the Invention

The present invention relates to biological testing and in particular to methods for determining
10 the presence or quantity of a subpopulation of analytes, having at least one characteristic determinant, within a population including such analytes, and to reagents and test kits used in performing such methods. The methods, reagents and
15 test kits of the invention facilitate screening of cells, viruses, and the like, by means of stably linking a detectable reporter substance to the lipid component of a biomembrane, separating the analyte of interest, e.g., via specific binding substances
20 affixed to a solid phase, and detecting the reporter substance.

Description of the Prior Art

Determinations of components of blood or bone
25 marrow, e.g., subpopulations of leukocytes, have become common clinical diagnostic tests due to the general availability of monoclonal antibodies selectively reactive with determinants of the discrete components. These determinations have proven useful
30 for monitoring changes in immunodeficiency diseases, leukemias, lymphomas and transplant patients. See: A. Landay and K. Muirhead, J. Clin. Immunopathol. (in press). Immunofluorescence labeling followed by flow

SUBSTITUTE SHEET

- 2 -

cytometric analysis is the established method for performing such determinations.

Flow cytometry has decided advantages over other commonly used cell marker analysis techniques, such as immunofluorescence microscopy, immunocytochemistry, and enzyme immunoassay. One significant advantage over bulk methods, e.g., fluorimetry or enzyme immunoassay, is the ability to simultaneously quantify multiple cellular subpopulations in one sample. Flow cytometry has several notable advantages over manual fluorescence microscopy. These include: (i) the ability of the instrument to rapidly score thousands of cells for positive or negative immunofluorescence, (ii) better reproducibility of results, (iii) permanent records of data, and (iv) greater sensitivity for detection of weakly fluorescing cells.

However, one distinct disadvantage of flow cytometry is that each sample must be run and analyzed individually. This disadvantage is particularly significant in a clinical laboratory which must process multiple patient specimen daily. The ability to quantitate cell subpopulations from multiple samples at once would substantially reduce the throughput time for this operation in the clinical or research laboratory.

One proposed method for analyzing multiple samples is enzyme-linked immunosorbent assay (ELISA). See: J. Endl. et al., J. Immunol. Meth., 102:77-83 (1987). This assay measures absorbance of multiple samples at one time using a 96-well microplate reader. The reporter system in this assay utilizes an enzyme, β -galactosidase, which is present in blood monocytes and neutrophils. Therefore, the blood specimen must be separated to remove interfering cells or cellular materials before performing this assay. Consequently,

SUBSTITUTE SHEET

5 this technique is not well-suited to determination of cell subpopulations in whole blood. Moreover, because this assay measures absorbance of the reporter molecule, it is less sensitive than a fluorescent detection system.

10 In the practice of immunofluorescence labeling and other immunoassay techniques, it is common to label antibodies directly with fluorescent, enzymatic or radioisotopic reporters. The number of such reporters that may be bound to an antibody molecule without changing its immunoreactivity, however, is quite limited. Moreover, the covalent bonding of a fluorochrome or radioisotopic reporter to an antibody requires compatible reactive groups on each reactant, which imposes another practical limitation on this sort of labeling.

20 In order to avoid direct labelling of fluorescent reporters to antibodies for use in flow cytometry and fluorescence microscopy, it has been proposed to use reagents comprising antibodies attached to liposomes loaded with dye molecules entrapped in the aqueous phase inside the liposomes. The increased number of reporter molecules per antibody has been found to enhance signal amplification. Furthermore, encapsulation of the reporter within the liposome permits a wider range of reporter molecules to be used, including those that cannot be directly bound to antibody. See: A. Truneh et al., J. Immunol. Methods, 100:59-71 (1987) and references cited therein; and U.S. Patent No. 4,372,745 to R. Mandle et al.

35 Similar reagents have been proposed for use in other diagnostic applications. The patent literature discloses immunoassays utilizing reagents in which a specific binding substance for an immunoreactive substance of interest is fixed on lipid

- 4 -

membrane-containing microcapsules, having a hydrophilic marker encapsulated in the microcapsules. In performing such immunoassays, a test sample containing the immunoreactive substance of interest is mixed with the reagent and a source of complement, causing the marker to be released from the microcapsules, after which its presence or quantity is determined by appropriate analysis. See, for example, Japanese Patents 60159652-A and 60017359-A. According to the specific embodiments disclosed in these references, the microcapsules are liposomes which are fixed to the specific binding substance via covalent bonds. See also: Japanese Patents 60138464-A, 60138465-A and 60138466-A. An additional advantage of this method is the ability to measure bound reagent in the presence of unbound reagent. However, this method also has several disadvantages. First, complement is a labile reagent and false negatives may result in this method from failure of complement to properly lyse liposomes and release reporter. Second, if the disclosed reagent were used to determine cell surface associated structures, complement could cause lysis of cells as well as liposomes, releasing substances which may interfere with measurement of some reporter molecules. Third, microenvironments within some test samples (e.g., low pH) may cause significant leakage and nonspecific release of some reporter molecules e.g., carboxyfluorescein. See: P. Machy et al., Proc. Nat. Acad. Sci. USA, 79:4818 (1982)).

Liposome reagents have also been proposed for use in determining soluble analytes, as described, for example, in U.S. Patents Nos. 4,717,676 and 4,698,263.

Another way of overcoming the above-noted limitation of directly coupling fluorescent reporter to antibodies in fluoroimmunoassays is described in U.S. Patent No. 4,576,912 to S. Yaverbaum et al. The

SUBSTITUTE SHEET

immunoassay technique disclosed therein involves the use of a reagent, comprising a carrier bearing a plurality of closely-packed fluorophores, which is coupled to an immunological reactant competitive with the immunological reactant of interest for binding to a known quantity of complementary binding substance. The fluorophores are sufficiently closely packed as to exhibit self-quenching and the reagent is capable of undergoing chemical treatment to release the fluorophores. A test sample and the reagent are mixed with a solid phase bearing the complementary binding substance for the immunological reactant of interest. After the competitive-binding reaction occurs, the bound immunological reactants and unbound immunological reactants are separated. The carrier, in either or both separated portions, is then chemically treated, or lysed, to liberate the otherwise quenched, closely-packed fluorophores to greatly enhance the measured fluorescence. The fluorescence intensity of the liberated fluorophores is then compared to a standard of known concentration to determine the amount of immunological reactant in the sample. This immunoassay technique is not without certain drawbacks, however, in that the chemical reaction used to effect reporter release prior to detection is typically a time consuming enzymatic reaction.

Another method for detection of cell surface antigens or antibodies thereto measures agglutination of fluorochrome labeled erythrocytes. V. Ghazarossian et al., Clin. Chem., 34:1720-25 (1988); see also U.S. Patent No. 4,748,129. This method has particular application for blood typing or the detection of antibodies to blood group antigens. Fluorochromes are used to label erythrocyte membranes and the presence of the antibodies or antigens is then determined from

fluctuations in the fluorescence signal (detected by a fiber optic probe) due to agglutination of the erythrocytes. This system can produce only qualitative or, at best, semi-quantitative results as to the presence or absence of antigens or antibodies of interest. Erythrocytes are stained by adding the dyes in organic solvent to whole blood where the dyes partition between the cells and the plasma. The dyes used in this assay (e.g., 1,3,-bis[4-diethylamino-2-hydroxyphenyl]-2,4-dihydroxycyclobutene-diylum dihydroxide) transfer from the erythrocytes to plasma during the assay, with the cells losing as much as 40% of the dye during a 10 minute incubation at 37°C. When the assay is employed to measure the presence of antibodies in plasma, erythrocytes in the blood sample are removed by the addition of colloidal magnetite particles and exposure of the sample to a magnetic field.

In diagnostic testing, it is often desirable to sort out and separate for further analysis a cell subpopulation or subset of interest from a mixed cell population.

One cell separation technique uses magnetic particles and magnetic affinity separation. Various methods for sorting biological populations by magnetic affinity separation have been described in the patent literature and in a number of periodical scientific publications. See, for example, U.S. Patents 3,970,518, 4,710,472, 4,677,067, 4,666,595, 4,230,685, 4,219,411, 4,157,323; see also, E.T. Menz, et al., Am. Biotech. Lab. (1986); J. S. Kemshead et al., Molec. Cell. Biochem., 67:11-18 (1985); T. Leivestad et al., Tissue Antigens, 28:46-52 (1986); and J.S. Berman et al., J. Immunol., 138:2100-03 (1987). In performing such methods, a receptor molecule (e.g., monoclonal antibody) is typically conjugated to the magnetic

SUBSTITUTE SHEET

- 7 -

particles, and added to a test sample under conditions causing binding to a characteristic determinant on the analyte of interest, after which the test sample is exposed to a magnetic field. See, for example, the immunomagnetic separation technique described by Leivestad et al., supra. The magnetic particles and analyte affixed thereto can then be separated from the rest of the population.

The use of magnetic affinity separation has been reported in clinical diagnostic immunoassays for soluble analytes which utilize a radioisotope (see, for example, Rattle et al., Clin. Chem., 30:1457-61 (1984) or fluorescent molecules (see, for example, Moscoso et al., Clin. Chem., 34:902-05 (1988); R.D. Nargessi et al., J. Immunol. Meth., 71:17-24 (1984); and Kamel et al., Clin. Chem. 26:1281-84 (1980)) as the reporter substance. The use of this technology to separate certain subpopulations of lymphocytes from bone marrow cells prior to transplantation, to eliminate post-transplantation graft vs. host reaction, has also been reported. See A. Butturini et al., Prog. Bone Marrow Transpl. 413-22 (1987). Other reported uses of this technology include the separation of tumor cells (see: Kempshed et al., B. J. Cancer 54:771-78 (1986)) and the separation of lymphocyte subpopulations for subsequent functional evaluation (Berman et al., supra).

The application of magnetic affinity cell separation to the quantitation of lymphocyte subsets in blood has been reported. See J. Brinchmann, Clin. Exp. Immunol., 71:182-86 (1988). In this procedure, blood samples were incubated with superparamagnetic polymer microspheres coated with monoclonal antibodies specific for distinct lymphocyte subpopulations. The cells bound to the microspheres were isolated from the rest of the population by

SUBSTITUTE SHEET

applying a magnetic field to the sample. The separated cells were then lysed to detach them from the microspheres, the microspheres and attached cell membranes were magnetically removed, and the resulting cell nuclei were stained and counted manually with a fluorescent microscope and hemacytometer. The number of nuclei counted corresponded to the number of cells in the sample in the subpopulation of interest. While this procedure may be used to enumerate the cells in a subpopulation of interest, manual enumeration of the cell nuclei is very time consuming and susceptible to technical error in sample loading of the hemacytometer and counting. Such a procedure would not be suitable for use in a clinical setting.

A need exists, therefore, for improved methods to determine analytes, particularly cell subpopulations. The characteristics of such improved methods should include: sensitivity comparable to or greater than methods heretofore available, ability to analyze multiple samples in a relatively brief time, and elimination of the need for expensive equipment and highly skilled personnel to perform the method.

SUMMARY OF THE INVENTION

According to one aspect of the invention, the determination of analyte having at least one characteristic determinant in a test sample suspected of containing such analyte, is performed by initially coupling the analyte of interest to a detectable reporter substance. The test sample is then contacted with a specific binding substance capable of interacting selectively with at least one characteristic determinant of the analyte of interest, under conditions causing complex formation between the analyte and the specific binding substance. Next,

SUBSTITUTE SHEET

the complexes thus formed are separated from any free analyte, so as to form two fractions. The occurrence of the reporter substance in one of the separated fractions is then detected. Ordinarily, the level of detected reporter substance is correlated to a predetermined standard to determine the presence or quantity of the analyte of interest within the test sample. This procedure is particularly useful for determining analytes which are biomembrane-containing entities, with the reporter substance being stably associated with the lipid content of the biomembrane. In a preferred embodiment of the invention, cell populations are analyzed, using the procedure just described, to determine the presence or quantity of a cell subpopulation of interest within the population.

In another aspect of the invention, analyte having at least one characteristic determinant is determined in a test sample by contacting analyte from the test sample with a reagent comprising a lipid-containing moiety, a specific binding moiety capable of selective interaction with the characteristic determinant of the analyte and a detectable reporter moiety which is stably associated with the lipid-containing moiety, under conditions causing binding of the reagent to the analyte. Thereafter, the occurrence of the detectable reporter substance bound to the analyte is detected.

Unlike some of the above-noted prior art analytical techniques, the methods of the present invention do not employ covalent coupling of reporter substances to a specific binding substance as a matter of choice. Rather, the reporter substance is preferably caused to become stably associated with the lipid component of the analyte or the lipid component of the reagent comprising the specific binding substance. By proceeding in this way, there is no

SUBSTITUTE SHEET

appreciable leakage of the reporter substance so long as the integrity of the aforesaid lipid component is maintained, yet the reporter substance may readily be dissociated from the analyte or reagent, as the case may be, by treatment with a suitable extractant. The use of extractable reporter substances in the methods of this invention constitutes a distinct advantage over related prior art procedures wherein the reporter is not extractable. Extractable fluorochromes provide a particular advantage when used as the reporter substance, as fluorescence efficiency may be increased by extraction and concentration of the fluorescent reporter prior to fluorescence measurement. Extractability of the reporter substance has an added advantage in that detection of an extractable reporter can be accomplished using relatively simple and inexpensive analytical devices and techniques, e.g., fluorometry instead of flow cytometry.

According to further aspects of the invention, reagents and test kits are provided for performing the above described methods. The reagents have been briefly described above. The test kits may include various components depending on the nature of the analyte sought to be determined. Test kits may include the detectable reporter substance for binding to the analyte(s) of interest, having a characteristic determinant, and a specific binding agent that selectively interacts with the characteristic determinant of such analyte, e.g. for use in cell determinations. Other components included in the test kits may be one or more media for coupling the reporter substance to analyte, an extractant for the reporter substance, one or more standards for determining the presence or quantity of the analyte(s) of interest in the test sample, or instructions for the preparation of such standard(s), and, optionally,

SUBSTITUTE SHEET

- 11 -

other accessories useful in carrying out the inventive methods.

Test kits for determining other analytes of interest having a characteristic determinant, such as allergens or autologous cells, may contain the above described reagent, comprising a lipid-containing moiety, a specific binding moiety that selectively interacts with the analyte determinant and a reporter moiety stably associated with the lipid-containing moiety.

The methods of the invention may be used as an adjunct to, and in certain instances as a replacement for the above noted analytical techniques currently applied in clinical laboratories, whose purpose is to screen for changes in cell frequency, e.g., flow cytometry. The methods described herein enable relatively rapid, simultaneous analysis of multiple biological samples with sensitivity comparable to that of the prior art. Moreover, the methods of the invention obviate the complex, expensive equipment and highly skilled personnel requirements of such prior art techniques.

Other advantages of the present invention will be apparent to those skilled in the art upon consideration of the drawing in conjunction with the detailed description of the invention presented below.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a standard curve showing fluorescence intensity as a function of reporter substance concentration for a series of solutions containing known concentrations of the fluorochrome 3-n-propyl-3'-n-docosanyloxacarbocyanine iodide (PDCI) as the reporter substance.

SUBSTITUTE SHEET

- 12 -

Fig. 2 is a graph representing the correlation between varying numbers of human mononuclear leukocytes coupled with 3-n-propyl-3'-n-docosanyloxacarbocyanine and fluorescence intensity of the reporter substance extracted from the same cells. The dashed line in Fig. 2 represents the average fluorescence intensity of an extract of the cell population which was not coupled to reporter.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for efficiently determining a broad range of analytes, which may be any constituent of a test sample or specimen whose presence or quantity may be determined by selective interaction with a specific binding substance. Thus, the term "analyte", as used herein, refers to a wide variety of substances of biological or medical interest which are measurable individually or as a group. Examples include cells, both eukaryotic (e.g., leukocytes, erythrocytes or fungi) and procaryotic (e.g., bacteria, protozoa or mycoplasma), viruses, cell components, molecules (e.g. proteins), and macromolecules (e.g. nucleic acids - RNA, DNA). These analytes may be determined as discrete entities or in the form of complexes or aggregates. Often it is desired to determine the presence or quantity of a subpopulation or subset of biomembrane-containing entities, i.e., analytes which contain naturally occurring lipid or phospholipid membranes, within a population. Examples include the determination of leukocytes within a population of blood cells, helper T lymphocytes within a population of lymphocytes, fetal cells within maternal circulation, virus-infected cells within a population of uninfected and infected cells, neoplastic cells within a population of normal and neoplastic cells, a

SUBSTITUTE SHEET

protein of interest within a population of many different proteins or the like. Such determinations are accomplished using the methods of the invention, which rely on the selective interaction of the
5 specific binding substance with at least one characteristic determinant of the subpopulation or subset of interest.

The term "determinant" is used herein in its broad sense to denote an element that identifies or
10 determines the nature of something. When used in reference to any of the foregoing analytes, "determinant" means that portion of the analyte involved in and responsible for selective binding to the specific binding substance, the presence of which
15 is required for selective binding to occur. Cell-associated determinants include, for example, components of the cell membrane, cytoplasm or nucleus. Among such cell-associated structures are membrane-bound proteins or glycoproteins, including
20 cell surface antigens of either host cell or viral origin, histocompatibility antigens, or membrane receptors. One class of specific binding substances used to selectively interact with these determinants are antibodies capable of immunospecifically
25 recognizing same. The term "antibody" as used herein includes immunoglobulins, monoclonal or polyclonal, and immunoreactive immunoglobulin fragments.

Further examples of characteristic determinants and their specific binding substances
30 are: receptor - hormone, receptor - ligand, agonist - antagonist, RNA or DNA oligomers - complementary sequences, Fc receptor of mouse IgG - Protein A, avidin - biotin, and virus - receptor. Still other determinant-specific binding pair combinations that
35 may be determined using the methods of the invention will be apparent to those skilled in the art.

SUBSTITUTE SHEET

- 14 -

The analyte of interest may be present in test samples or specimens of varying origin, including biological fluids such as whole blood, serum, plasma, urine, cerebrospinal fluid, amniotic fluid, lavage fluids and tissue extracts. In certain applications of the methods of the invention, the analyte may be adsorbed or immunologically captured onto a suitable solid support. Accordingly, it is within the scope of the present invention to detect, among other things, antigens, epitopes, antibodies, haptens or antigen-antibody complexes in biological fluids, autoantibodies bound to autologous cells in suspension and viral infections.

According to a preferred embodiment of the invention, analysis is performed on cell suspensions or populations including subpopulations and/or subsets expressing a characteristic integral membrane determinant to establish the total number of cells of interest within a sample cell suspension, or to determine the proportion of a cell subset within a cell subpopulation. Such cells of interest include cells of human or animal origin, cultured cells, as well as some single-celled organisms and virions. Cells of particular interest in current investigation include human and animal hemopoetic cells, including stem cells, progenitor cells of different lineages, cells at different stages of differentiation within a lineage, and mature forms of various lineages. Of particular interest in diagnostic, therapeutic and research applications are mammalian lymphocytes, including B cells, T cells and recognized T cell subsets, such as helper T cells, suppressor T cells and cytotoxic T cells. Different lineages of cells are characterized by expression of characteristic antigens or ligands. For example, B cells from mammalian blood samples express surface ligands

SUBSTITUTE SHEET

distinct from those expressed by T cells from the same sample. Quantitation of one cell subset from the sample may be important in assessing certain pathological conditions. For example, individuals
5 infected with human immunodeficiency virus (HIV) are tested for T helper cells bearing CD4 glycoprotein for purposes of determining the stage of disease and monitoring treatment. As another example, an
10 abnormally large proportion of a single B cell clone in a patient's blood may be indicative of a leukemic condition. Cells from the same lineage at different stages of differentiation are also distinguishable by expression of characteristic antigens or ligands. For example, as a B lymphocyte develops from a stem cell
15 to a pre-B cell and ultimately to a mature B cell, the cell membrane markers change in a predictable manner as the cell matures. A mature B cell expresses immunoglobulins as ligands on the cell membrane, whereas a pre-B cell expresses only cytoplasmic
20 immunoglobulin heavy chains, which provides the basis for differential reactivity of these cell subsets, permitting subsequent determination. Differential expression of ligand can further provide a basis for assessing pathogenesis such as viral infection.
25 Virally infected cells may express viral markers which are absent from uninfected cells within the cell population. These viral markers may be found intracellularly or on the cell membrane.

In analyzing cell populations for
30 subpopulations or subsets of interest according to the above mentioned preferred embodiment, the cell population, suspended in a suitable biological or synthetic medium, is initially coupled to a detectable reporter substance. The expression "reporter
35 substance" is used herein to refer to any substance whose detection or measurement, either directly or

- 16 -

indirectly, by physical or chemical means, is indicative of the presence of the analyte of interest in the test sample. Examples of useful reporter substances include, but are not limited to the following: molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties. Included among the group of molecules indirectly detectable based on light absorbance or fluorescence, for example, are various enzymes which cause appropriate substrates to convert, e.g., from non-light absorbing to light absorbing molecules, or from non-fluorescent to fluorescent molecules. Fluorochromes, i.e., any of various fluorescent compounds used in biological staining to produce fluorescence in a specimen, are particularly useful as reporter substances in the practice of this invention. Representative fluorochromes are those selected from the group of cyanine, acridine, pyridine, anthraquinone, coumarin, quinoline, xanthene, phenoxazine, phenothiazine and hexatriene dyes and derivatives thereof.

One of the distinctive aspects of this invention involves the coupling of the lipid component of the aforesaid biomembrane-containing entities (including such entities associated with specific binding substances) to a unique class of reporter substances capable of stable association with such lipid component. The expression "stable association", used herein to describe the manner in which the reporter substance is linked to the lipid component of the biomembrane, is intended to mean that the affinity of the reporter substance for the lipid component of

SUBSTITUTE SHEET

the membrane is greater than for the surrounding medium. The affinity of the below-described reporter substances for cell membranes is sufficiently strong that the reporter substance remains associated with the lipid component of the membrane even when exposed to conditions or agents having a tendency to cause leakage or loss of materials from membrane-containing microcapsules. See e.g., P. Machy et al., Proc. Nat. Acad. Sci., U.S.A., 79:4148 (1982); and Monroe, Amer. Biot. Lab, 5:10-19 (1987). Unlike previous cell labelling methods, see for example, V. Ghazarossian et al., Clin. Chem., 34:1720-25 (1988) and U.S. Patent No. 4,748,129, this stable association between the reporter substance and the lipid component of a cell membrane is lost only when subject to conditions or agents which disrupt or destroy the integrity of the membrane's lipid component, such as by contact with detergents or lipid solvents which dissolve or disperse the lipid component.

On a quantitative basis, the expression "stably associated with" signifies that greater than 90% of the reporter substance initially linked to the lipid component of the cell membrane remains linked with the cell population or other biomembrane-containing entities throughout the course of the analysis (as detected by physical separation of cells from disassociated reporter substance), which is generally on the order of three hours.


Reporter substances capable of stable association with the lipid component of a biomembrane may comprise substances that are entirely hydrophobic in character, or that may include a moiety having at least one hydrophobic portion or domain serving to anchor the reporter molecule to such lipid component. In the latter instance, the hydrophobic portion of the reporter molecule should associate the molecule to

SUBSTITUTE SHEET

- 18 -

lipid sufficiently to cause it to remain stably associated with the lipid, even in an agitated solution or disrupted cell suspension.

A particularly suitable group of reporter substances is represented by the formula:



10

wherein R and R₁ are the same or different and represent substituents independently selected from the group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which having from 1 to 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R₁ having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R₁ being at least 23;

15

20

X and X₁ may be the same or different and represent O, S, C(CH₃)₂ or Se;

Y represents a linking group selected from -CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or -CH=CH-CH=CH-CH=CH=;

25

Z and Z₁ may be the same or different and represent substituents selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, NHNH₂, NCS, NCO, CONH-alkyl, CON-(alkyl)₂, NH-acyl, O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and A represents a biologically compatible anion.


30

35

SUBSTITUTE SHEET

- 19 -

A sub-group of useful reporter substances within the above-described group includes compounds of the formula:




wherein R and R₁ are the same or different and represent alkyl substituents, having from 1 to 30 carbon atoms, and being linear or branched, unsubstituted or substituted with halogen, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear atoms in R and R₁ being at least 23;

15 Z and Z₁ may be the same or different and represent substituents selected from the group H, or lower alkyl having from 1 to 3 carbon atoms; and A represents a biologically compatible anion.

Of the compounds represented by formula II, suitable reporter substances are 3-n-pentyl-3'-n-octadecyloxacarbocyanine iodide, 3-n-octyl-3'-n-octadecyloxarcarbocyanine iodide, 3-n-propyl-3'-n-eicosanyloxacarbocyanine iodide, and 3-n-propyl-3'-n-docosanyloxacarbocyanine iodide.

25 Yet another subgroup of useful reporter substances within the above-described group includes compounds of the formula:



SUBSTITUTE SHEET

- 20 -

wherein R and R₁ are the same or different and represent alkyl substituents, having from 1 to 30 carbon atoms, and being linear or branched, unsubstituted or substituted with halogen, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear atoms in R and R₁ being at least 23;

Z and Z₁ may be the same or different and represent substituents selected from the group H, or lower alkyl having from 1 to 3 carbon atoms; and A represents a biologically compatible anion.


Among the compounds represented by formula III, suitable reporter substances include:

1,1'-di-n-octadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate;

1-n-octadecyl-1'-n-pentyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; and

1-n-docosanyl-1'-n-propyl-3,3,3',3'-tetramethylindocarbocyanine iodide.

A further group of useful reporter substances includes compounds of the formula:



wherein R represents a substituent selected from the group of alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chain of which is linear or branched, said substituent being unsubstituted or substituted with one or more non-polar functional groups, and having at least 23 linear carbon atoms;

Z, Z₁ and Z₂ may be the same or different and represent substituents selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, NHNH₂, NCS,

SUBSTITUTE SHEET

- 21 -

NCO, CONH-alkyl, CON-(alkyl)₂, NH-acyl, O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂, halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and A represents a
5 biologically compatible anion.

Of the compounds represented by formula IV, a suitable reporter substance is 3,6-bis(dimethyl-amino)-10-n-hexacosanyl acridinium iodide. Other suitable fluorochrome compounds are
10 4-[4-didecylaminostyryl]-N-methyl-pyridinium iodide, N-3[3-Sulfopropyl]-4-[p-didecylaminostyryl] pyridinium inner salt and 2-[3-(1-n-docosanyl-benzoxazol-2-yliden)-1-propenyl]-6-iodo-1-n-tetradecyl-benzothiazolium iodide.

15 As used in the preceding description of the reporter substance, the term "non-polar functional group" refers to substituents such as O-alkyl, S-alkyl, halogen, N(alkyl)₂, Se-alkyl, NO, CN, CO-alkyl, C=N-alkyl, -SiMe₃, O-SiMe₃, and the like.

20 Alternatively, the reporter substance may comprise a substantially hydrophobic chelate-metal complex, preferably wherein the chelate-metal complex comprises a metal ion selected from the transition metal series whose atomic number is from 21-29, the
25 lanthanide series whose atomic number is 59-66 and the actinide series whose atomic number is 91, said complex being detectable by nuclear magnetic resonance or luminescence. The chelate-metal complex may also comprise a paramagnetic metal ion selected from the
30 group of Gd, Cr, Dy, Ni, Cu, Fe and Co.

The reporter substance may also comprise a substantially hydrophobic substance incorporating a detectable radioisotope. The radioisotope incorporated into the reporter substance is preferably
35 selected from the group of radioactive carbon,

SUBSTITUTE SHEET

hydrogen, nitrogen, phosphorus, fluorine, chlorine, iodine, sulphur, selenium, cobalt and chromium.

The foregoing classes of hydrophobic reporter substances, are described in further detail, along
5 with preparative procedures for specific compounds, in copending U.S. Patent Application Serial No. 189,192, which is commonly assigned with the present application. The entire disclosure of Serial No. 189,192 is incorporated in this specification by
10 reference, as if set forth herein in full. The indocarbocyanine dyes are readily prepared following the general reaction scheme for oxacarbocyanine dyes set out in Serial No. 189,192, substituting the appropriate indole derivatives for the benzoxazole
15 derivatives used as starting materials in the reaction there described.

The reporter substances just described are characterized by having relatively long chain hydrocarbon substituents or "tails" that impart the
20 requisite hydrophobicity/lipophilicity for stable association with the lipid-containing analytes or reagents. Once these compounds become bound to lipid, they cannot easily dissociate. Consequently, the reporter substance does not leak from the analytes or
25 reagents and is not liable to be transferred to other biomolecules or cell-associated structures.

Details regarding the coupling of the above-described reporter substances to biomembrane-containing entities are provided in U.S.
30 Patent No. 4,783,401 to Horan et al., the entire disclosure of which is incorporated in this specification by reference, as if set forth herein in full. In general, coupling of the reporter substance to cells involves suspension of the cells in a
35 suitable medium, e.g., 300 mOs per liter sucrose, at a concentration of 10^7 to 10^9 ml., followed by addition

SUBSTITUTE SHEET

of the reporter substance to the cell suspension in an amount of about 1-20 μ M and incubation of the suspension for about 5 minutes, at about 20-30°C.

Determination of analytes according to the methods of the invention is accomplished by reason of the selective interaction between the analyte of interest and a specific binding substance. The specific binding substance used in the methods must exhibit selective recognition for the characteristic determinant of the analyte. The specific binding substance selected for a particular analysis will depend on the nature of the analyte being determined. In analyzing a cell population for a subpopulation and/or subset having a characteristic cell surface antigen, for example, the specific binding substance may be the complementary antibody that immunospecifically recognizes the antigen of interest. Based on such selective recognition, the specific binding substance is capable of selective interaction and binding with the analyte of interest to form complexes or aggregates which are physically or chemically separable from the test medium and other components therein which are not of interest.

Specific binding substances are conveniently affixed to a solid phase to facilitate separation from the test medium. Techniques for immobilizing antibody on a solid support, e.g., polystyrene, nylon or agarose beads, are well known to those skilled in the art. Suitable techniques include cross-linking, covalent binding or physical adsorption. Alternatively, a non-solid phase, primary specific binding substance may be used in conjunction with a second or auxiliary specific binding substance which is capable of interacting selectively with the primary specific binding substance, and which is affixed to a solid phase. Representative primary and auxiliary

SUBSTITUTE SHEET

- 24 -

specific binding substances useful for this purpose are: soluble murine antibody/Protein A affixed to a solid phase; soluble murine antibody/anti-mouse immunoglobulin raised in another species and affixed to a solid phase; biotinylated antibody/avidin affixed to a solid phase.

In a particularly preferred embodiment of the invention, the specific binding substance is affixed to a magnetic solid phase, which may comprise ferromagnetic, paramagnetic or diamagnetic material, thereby forming complexes or aggregates with the analyte of interest which are magnetically separable from the test medium. Suitable procedures for coupling specific binding substances to a magnetic solid phase, e.g., magnetite particles, are described in the literature. See, for example, E. Menz et al., Am. Biotech. Lab. (1986).

After separation of the analyte of interest from the test medium, detection of the reporter substance provides a basis for determining the occurrence of interaction between the analyte and the specific binding substance. The reporter substance may be detected in the separated analyte of interest, i.e., in the analyte/specific binding substance complexes, or in the test medium remaining after separation of the analyte of interest, which is substantially free of such complexes. The former procedure is preferred. The level of reporter substance detected in the separated analyte or in the remaining test medium may be correlated to a predetermined standard. Correlation to a standard may be employed whether the analyte determination is qualitative or quantitative. In a qualitative determination, the predetermined standard may be a negative control known to be free of the analyte of interest. Detection of the reporter substance in

SUBSTITUTE SHEET

amounts appreciably higher than the background level of the negative control is indicative of the presence of the analyte of interest. In a quantitative determination, the level of detected reporter
5 substance is compared to the level detected in e.g., one or more measured quantities of analyte, so as to establish the relative or absolute quantity of analyte of interest in the test sample. Quantitative
10 determinations usually involve the preparation of a standard curve, containing increasing known quantities of reporter substance. These known quantities of reporter substances are plotted against the level of reporter substance detected. A typical standard curve
15 for use in practicing the present invention is shown in Figure 1. Based on the standard curve, the quantity of analyte in a test sample may be derived from the level of reporter substance detected therein.

The predetermined standard for quantitative determination of analyte may be in various forms.
20 Representative examples include compositions containing a measured number of membrane-bounded entities coupled to a measured amount of the detectable reporter substance, or a measured amount of reporter substance extracted from such entities, as
25 shown in Figure 2. The membrane-bounded entities comprising the standard may be the same as the entities being determined, naturally occurring biomembrane-containing entities of a different species, e.g., animal cells, organelles or the like,
30 or non-naturally occurring membrane-bounded entities, having synthetic membranes composed of lipids or phospholipids, such as liposomes or micelles. The synthetic membrane bounded entities may be prepared with the reporter substance stably associated with the
35 membrane lipid, e.g., according to the procedure, described in copending U.S. Patent application Serial

No. 238,958, filed August 31, 1988, the entire disclosure of which is incorporated in the present specification by reference, as if set forth herein in full. Alternatively, in the case of liposomes, for example, the reporter substance may be included in the aqueous phase, encapsulated by the lipid bilayer, and later extracted by the action of a suitable lysing agent, as is known in the art. See, for example, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1986).

The reporter substance may be detected in several ways. The presence of reporter substance coupled to cells in either of the above-mentioned separated portions of the test medium may be determined directly from measurement of the individual cells and solution using automated methodology. Alternatively, the reporter substance may be removed by solvent extraction from the other components of the cell complexes. Extraction of the reporter substance is desirable in order to obtain a homogeneous distribution of the reporter substance for accurate analysis. In many cases, the unit absorbance (e.g., extinction coefficient) or fluorescence (e.g., quantum yield) of the reporter substance is greater after extraction, thereby increasing the detection sensitivity of the reporter substance. Extraction of the reporter substance may also be desirable to avoid potential interference with the measurement due to cellular material. Among the suitable extractants which may be used to dissociate the above-described reporter substances from biomembranes are butanol, ethanol or aqueous detergent solutions, e.g. Triton™ X-100.

The foregoing method of the invention may be applied in analyzing a subpopulation of cells, present within a cell population, to determine the

SUBSTITUTE SHEET

proportional occurrence therein of at least one cell subset of interest. This method may be applied, by way of example and not by way of limitation, to the determination of: lymphocyte, monocyte, and
5 neutrophil subsets of a leukocyte subpopulation in a whole blood cell population; T cells and B cells of a lymphocyte subpopulation in a leukocyte population; or helper T cells and suppressor T cells of a T lymphocyte subpopulation in a total lymphocyte
10 population. In order to determine the proportional occurrence of a subset of cells in this way, it is necessary to determine the relative number of cells in the individual subsets of interest as well as the relative number of the individual subsets of interest
15 within the same sample or a sample of equivalent volume and cell concentration.

In carrying out this determination, substantially all of the cells comprising the population suspected of containing the subpopulation
20 of interest are coupled to a detectable reporter substance, such that the reporter substance is stably associated with the membrane of the cells. A first reagent is provided which incorporates at least one specific binding substance capable of selectively
25 interacting with a characteristic determinant of the cell subpopulation. The first reagent may also comprise a mixture of specific binding substances, each binding to characteristic determinants of the individual subsets of interest within the cell
30 subpopulation, so that substantially all cells of the subpopulation become bound to the first reagent. For example, a number of monoclonal antibodies which interact selectively with the characteristic antigens of a defined number of cell subsets may be
35 incorporated into the first reagent. The first reagent is contacted with a first sample of the

SUBSTITUTE SHEET

population under conditions causing binding of the first reagent to cells of the subpopulation, so as to form first complexes in the sample. Next, the complexes thus formed are separated from unbound cells in the first sample and the occurrence of reporter substance in the separated complexes is detected. This procedure establishes the relative or absolute number of cells within the cell subpopulation of interest.

10 Thereafter, a second sample of the cell population to which the detectable reporter substance has been coupled, as described above, having volume and cell concentration equivalent to the first sample, is contacted with a second reagent comprising one or more specific binding substances that selectively interacts with a characteristic determinant of a cell subset of interest, under conditions causing binding of the second reagent to such determinant, so as to form second complexes in the second sample. The second complexes are separated from unbound cells in the second sample and the occurrence of reporter substance in the second complexes is detected.

25 The proportion of the subset of interest in the cell subpopulation is determined by quantitating the amount of reporter substance associated with the second complexes relative to the amount of reporter substance associated with the first complexes. In general, the level of detected reporter substance in each subpopulation and/or individual cell subset of interest may be related to a predetermined standard, in the manner previously described, to determine the presence or quantity of the cell subpopulation and/or cell subset of interest in the sample undergoing analysis. This determination of proportional subsets of interest is conveniently performed using reagent affixed to a solid phase, which preferably comprises

SUBSTITUTE SHEET

magnetic material to facilitate separation from the test medium, and an extractable reporter substance.

If the population contains additional cell subsets of interest, additional reagents may be prepared, each reagent comprising one or more specific binding substances that selectively interact with a characteristic determinant of one of the additional subsets of interest. The additional reagents are contacted with additional samples of the above-mentioned cell population, each sample once again being of equivalent volume and cell concentration to the first sample, under conditions causing the formation of additional complexes between the additional reagents and cell subsets of interest in the additional samples. Detection of the reporter substance in the complexes separated from each additional sample provides an indication of the proportional occurrence of the individual subsets of interest within each sample. Thus, the proportional occurrence determination of subsets in the additional samples is carried out in the same manner as the determination of the cell subset of interest in the second sample, described above.

As previously noted, analyte may be determined in accordance with this invention by a method in which the detector substance is coupled with a specific binding substance, rather than with the analyte. Specifically, a reagent is used which comprises a lipid-containing moiety, a specific binding moiety capable of selective interaction with the characteristic determinant of the analyte and a detectable reporter moiety which is stably associated with the lipid-containing moiety. This method may be implemented on the basis of non-competitive binding interaction or competitive binding interaction between the analyte and its specific binding substance. The

SUBSTITUTE SHEET

non-competitive binding procedure is conveniently performed by immobilizing analyte from the test sample, contacting the immobilized analyte with the reagent under conditions causing binding of the reagent to the analyte and determining the occurrence of the detectable reporter substance bound to the immobilized analyte. The parameters for practicing this method are essentially the same as those set forth above in relation to the earlier described method in which the reporter substance is coupled to the analyte. In the competitive binding procedure, the step of contacting the test sample with the specific binding substance includes adding to the test sample a known quantity of the analyte to be determined, thereby to effect competition between any analyte originally present in the test sample and the added analyte for complex formation with the specific binding substance. The presence or quantity of the analyte of interest in the test sample is determined in accordance with conventional competitive binding assay techniques.

This method is suitably used, for example, in the early determination of viral infection. In performing this determination, a reagent is prepared from biomembrane-containing entities bearing natural or induced receptors for viral determinants or viral-induced determinants in the host cell. The membrane of these entities is stably associated with one of the above-described reporter substances. The resultant reagent is then incubated with the infected cells. The infected cells bearing the reporter substance may be identified microscopically, or, if desired, the extent of infection may be determined by extracting and quantitating the reporter substance. Similarly, analyte from a biological sample, e.g., patient serum, may be immobilized on a solid support,

SUBSTITUTE SHEET

- 31 -

and its presence or quantity determined by interaction with a reagent comprising analyte receptor-bearing cells, which are coupled to one of the above-mentioned reporter substances, and determining the level of receptor substance bound to the solid phase. This technique may be used, for example, in allergen testing, using IgE receptor-bearing cells or red blood cells linked to anti-human IgE, each being coupled to a reporter substance. Replacement of radiolabeled antibody, typically used in allergy testing, with a reagent of the invention coupled to an extractable fluorochrome, for example, would allay the concern of many clinicians about the use of radioactive reagents. In addition, autoantibodies bound to autologous cells may be identified using this method, by incubating autoantibody-bearing autologous cells with a reagent comprising IgE receptor-bearing cells coupled to a suitable reporter substance, isolating the resulting complexes via affinity separation and detecting reporter substance. This method may also be used in identifying and/or quantitating antigens or epitopes of interest, e.g., using antigen- or epitope-specific T or B cell clones.

In a variation of this embodiment of the invention, the presence or quantity of multiple analytes in a test sample is determinable, provided of course that each analyte has a characteristic determinant. For example, identification or quantitation of more than one cell subpopulation and/or cell subset within the same population can be achieved by means of this method. Such a cell population may contain or be suspected of containing two or more cell subsets, among other subsets, which for purposes of this discussion, are designated cell subset A and cell subset B, and which express determinant X and determinant Y, respectively, as

SUBSTITUTE SHEET

characteristic markers. The determination of the presence and/or quantity of cells of cell subset A and cell subset B in the sample in clinical or experimental analysis can be efficiently done according to the latter method of the invention following a number of related protocols. Basically, the method involves preparing one specific binding substance that selectively interacts with cell subset A via a selective binding reaction with determinant X, thereby forming complexes between cell subset A and the one specific binding substance. Another specific binding substance is prepared that selectively interacts with determinant Y expressed by cell subset B.

In one protocol, discrete samples of the cell population of equivalent volume and cell concentration may be reacted serially with the one specific binding substance and then with the other specific binding substance. Following reaction and separation of complex from each reaction mixture, the reporter substance may be quantitated from each sample to provide an indication of the amount of cell subset A and the amount of cell subset B in the population. In this protocol, the reporter substance used in each of the reagents may be the same or different. Of course, additional specific binding substances may be prepared and used as needed for determination of other different cell subsets.

In an alternative protocol, the two specific binding substances may be reacted in the same sample of the population by adding and incubating both specific binding substances together to form discrete complexes within the sample. The resulting complexes are discrete due to the selective affinity of each specific binding substance for its respective different cell subset determinant. When the complexes

SUBSTITUTE SHEET

are separated from the reaction, the total complexes will contain cell complexes formed by each of the selective reactions. In this protocol, the reporter substance coupled to the one specific binding
5 substance must be distinguishable or separable from the reporter substance coupled to the other specific binding substance to permit distinct readings of the two cell subsets by detection of the two reporter substances. In this regard, the reporters may
10 comprise substances having distinct spectral properties, by which is meant sufficiently differing excitation wave length(s), emission wavelength(s) or fluorescence lifetime(s), such that detection of the presence of one reporter substance is not compromised
15 by the presence of any other reporter substance, i.e., the values determined for one are not significantly affected by the presence of the other. The use of such reporter substances permits individual measurement of each reporter independently of one or
20 more other reporters present in the complexes. Alternatively, the one reporter may be physically separable from the other(s), e.g., by reason of its solubility.

The reagents used in the just described
25 method are also within the scope of the present invention. Reagents of the invention may include specific binding substances that occur naturally on the surface of specific cells, such as hormone receptors, antibody on the surface of B lymphocytes or
30 virus receptors on the surface of susceptible cells, e.g., helper T lymphocytes or monocytes having the surface glycoprotein CD4 are susceptible to HIV infection. Other specific binding substances which may be used in these reagents are substances expressed
35 on cell surfaces after specific biological events that alter the cells. For example, interleukin-2 (IL-2)

SUBSTITUTE SHEET

receptor is expressed at high levels on the surface of activated T lymphocytes, but at very low levels on the surface of resting lymphocytes. Similarly, viral antigens may be expressed on the surfaces of infected cells only. These are but two examples of receptor expression induced through physiologic activation. Other such examples will occur to those skilled in the art. Cells may also be transformed or transfected by recombinant DNA technology, to express specific binding substances on their surfaces. In each of these examples, the lipid containing moiety and the specific binding moiety occur naturally or are induced in a single entity, with the reporter substance being stably associated with the lipid moiety, i.e., the lipid component of the cell membrane.

The reagents of the invention may comprise cells, which are modified to incorporate specific binding substances, such as antibodies or antibody fragments that selectively interact with the characteristic determinant of the analyte of interest. Such modified cells can be prepared by linking to the cell surface a derivatized antibody or antibody fragment having at least one lipophilic hydrocarbon substituent. The hydrocarbon substituent must be of appropriate length to render the derivatized antibody or antibody fragment sufficiently non-polar as to have a surface membrane retention coefficient of at least about 90 during a 24 hour period in saline containing up to 10% serum, with the percent change in such coefficient during such period being less than 10%. Details of the procedure for preparing such derivatized antibodies or antibody fragments are provided in the aforementioned U.S. Patent application Serial No. 189,192. In addition, a hydrocarbon group of appropriate length and functionality may be embedded into the plasma membrane of the cells and

SUBSTITUTE SHEET

thereafter coupled to the antibody or antibody fragment using procedures known in the art. Coupling of the resultant derivatized antibodies or antibody fragment to cells may be carried out in the manner described in the aforementioned U.S. Patent No. 4,783,401.

The reporter moiety of the reagent may be any of the reporter substances described above in connection with the analyte determination methods of the invention.

The methods of the invention may be performed using conventional containers, including test tubes, multiwell plates, and the like. Detectors for accurately measuring the level of reporter substance in a test sample, such as a colorimeter, a spectrophotometer, a fluorospectrophotometer, a liquid scintillation counter or a gamma counter, are commercially available.

According to another aspect of the invention, pre-measured quantities of the different reagents, together with the various accessories used in practicing the methods of the invention, including diluents, extractants, solid supports for immobilizing analyte, one or more standards, or instructions for the preparation thereof may be conveniently packaged in a test kit. The reagents in the test kit may take various forms. The reporter substance may be provided in the form of a solution, together with a suitable diluent for coupling reporter to cells. The reporter solution may be provided in a container suitable for performing the methods of the invention. Alternatively the reporter substance may be packaged dry, together with separate vials of diluent or solvent for addition to the reporter and/or other reagents in the course of carrying out the methods. The specific binding substance is preferably provided immobilized

SUBSTITUTE SHEET

on a solid support, which may be suspended in a suitable buffer, lyophilized or dried.

The following examples are provided to describe the invention in further detail. These examples are intended to illustrate specific applications of the methods of the invention and should in no way be construed as limiting the invention. All solvent proportions are given by volume and all temperature in °C, unless otherwise indicated.

Example 1 - Relationship between fluorescence intensity of extracted fluorochrome substance and cell number

Peripheral blood mononuclear cells were prepared from whole blood of a healthy donor by density gradient centrifugation. This preparation contains primarily lymphocytes and monocytes. The cells were coupled with 3-n-propyl-3'-n-docosanyloxacarbocyanine iodide (PDCI), using 10uM of this reporter and 1×10^7 cells/ml, with 300 mOs per liter sucrose as the diluent. The resultant cells were incubated with reporter for 5 minutes at room temperature in a polypropylene tube. The coupling reaction was stopped by the addition of phosphate buffered saline (PBS) with 5% (w/v) bovine serum albumin (BSA). Cells were centrifuged at 350x g and the resulting pellet was washed twice with PBS with 1% BSA. Cell recovery after coupling with the reporter was 73% with 94% of the cells viable. Viability was determined by propidium iodide exclusion, according to the procedure described by C. Yeh et al., J. Immunol. Meth., 43:269-75 (1981).

Dilutions of the cell suspensions were prepared and aliquots corresponding to 500 - 100,000 cells were placed in wells of a 96 well culture plate. The plate was centrifuged at 350 x g and the

supernatants were decanted. Each pellet was resuspended in 250 ul of 1% Triton X-100 in PBS and incubated for 5 minutes at room temperature. An aliquot of the cell extract (200 ul) was removed from each well and placed in a 96 well flat bottom reading plate made of black plastic.

Additionally, dilutions of PDCI in Triton X-100 (0.005 μ M to 1 μ M of PDCI) were placed in another reading plate. This plate was used to establish a standard curve.

The fluorescence intensity of each sample in the reading plates was measured on a Fluoroskan™ II microplate reader (Flow Laboratories, Inc.) using 485 nm excitation filter and 538 nm emission filter.

As can be seen from Fig. 1, the fluorescence intensity of PDCI analyzed by the Fluoroscan II microplate reader is proportional to the concentration of PDCI. Fig. 2 shows that the fluorescence intensity of PDCI extracted from the cells is proportional to cell number. The data appearing in Fig. 2 further indicate that this analytical technique can detect less than 1000 or less PDCI-coupled cells after extraction.

Example 2 - Determination of the proportion of cells in subpopulations of leukocytes by immunoaffinity separation and extraction of fluorochrome reporter substance from cells coupled therewith

5

Peripheral blood mononuclear cells were collected from healthy donors and stained with PDCI (2 μ M concentration), as described above in Example 1. The resultant cells were suspended to a final concentration of 1×10^7 /ml in wash buffer consisting of PBS with 1% BSA and 40 μ M EDTA (ethylenediamine-tetraacetic acid).

10

Aliquots of PDCI-coupled cells were incubated with monoclonal antibodies (Mab) specific for lymphocyte subsets at a concentration of 20-40 μ l Mab per 2×10^6 cells. The Mabs used were: anti-CD4, specific for helper T lymphocytes and monocytes; anti-CD8 recognizing suppressor/cytotoxic T lymphocytes; anti-CD19, specific for B lymphocytes, and a negative control Mab of the IgG₁ isotype. All Mabs were from AMAC, Inc. Cells were incubated with the Mabs for 30 minutes at 4°, washed twice in wash buffer, resuspended in 200 μ l of wash buffer and placed in 4 ml polypropylene tubes. Then 50 μ l of goat anti-mouse immunoglobulin conjugated to magnetic beads (Dynal Inc.) was added to each tube and the tubes were incubated for 30 minutes on a blood mixer (Robbins Scientific) at 4°.

15

20

25

30

35

The magnetic beads, and cells bound to the beads, were separated by adding 1 ml of wash buffer to the tube and then placing the reaction tube adjacent to a magnet for 1 minute. The supernatant, containing reaction fluid and unbound cells, was removed. The magnet was removed and 1 ml of wash buffer was added to the tube with gentle mixing to resuspend the

SUBSTITUTE SHEET

- 39 -

resultant pellet. The magnet was reapplied as above and the supernatant was decanted. This procedure was repeated again. All of the supernatants from each reaction tube were pooled. After the last wash, the pooled supernatants were centrifuged and the cells were resuspended in 200 ul of wash buffer. The washed pellets from the magnetic separations were also resuspended in 200 ul wash buffer.

Aliquots (150ul) of each tube (those containing washed pellets and those containing cells from pooled supernatants of the magnetic separation) were transferred to wells of a 96 well plate. The plate was centrifuged and the supernatant decanted. Then the cells in each well were resuspended in 250 ul of 1% Triton X-100 to extract the PDCI. The extracts were analyzed on a Fluoroskan II plate reader as described above in Example I; this instrument performs fluorescence determination on up to ninety six (96) extracts in less than one minute. The percentage of Mab labeled cells was calculated as:

$$\frac{\text{Fluorescence intensity of pellet}}{\text{Fluorescence intensity of (pellet + supernatant)}} \times 100\%$$

Aliquots of cells from the same donor, which were not stained with PDCI, were used for immunofluorescence labeling. These samples were incubated with the same Mabs as above, then reacted with phycoerythrin conjugated goat anti-mouse immunoglobulin (Biomed, Corp.). The immunofluorescence labeled cells were analyzed by flow cytometry, which is a method commonly used heretofore for this determination. Flow cytometry typically requires about one minute per fluorescence determination. The percentage of Mab labeled cells was calculated as:

SUBSTITUTE SHEET

Number of immunofluorescence positive mononuclear cells x 100%
Total number of mononuclear cells counted

The results of these determinations were:

Table I

5	Mab	<u>Specimen 1</u>		<u>Specimen 2</u>	
		Magnetic Separation	Flow Cytometry	Magnetic Separation	Flow Cytometry
	Anti-CD4	64.0%	63.7%	51.7%	47.2%
10	Anti-CD8	21.6%	24.8%	20.9%	19.6%
	Anti-CD19	12.2%	6.0%	7.5%	5.8%
	IgG1 control	4.6%	2.7%	5.6%	1.6%

15 These results show that the proportion of
cell subsets in a population expressing characteristic
antigens can be determined by the method of the
invention and that the results obtained by this method
are comparable to those obtained by the conventional
20 flow cytometric analysis and that for large numbers of
fluorescence determinations, the method of the
invention requires significantly less analysis time
than the conventional method.

25 While certain embodiments of the present
invention have been described and exemplified above,
various other embodiments will be apparent to those
skilled in the art from the foregoing disclosure. For
example, antigen-specific cells involved in
cell-mediated immunity may be determined utilizing the
30 present invention. This determination is performed by
coupling all immune cells in a test sample with one of
the above-described reporter substances capable of
stable association with the lipid component of the
membranes of the immune cells, incubating the cells
35 bearing the reporter substance with the antigen of
interest bound to a solid support, separating unbound

SUBSTITUTE SHEET

cells, extracting the reporter substance and determining the presence or quantity of antigen-specific cells bound. In addition to identification of specific immune cell subsets, the present invention may be used for making similar determinations in any other system where a panel of monoclonal antibodies is available, e.g., identification of bacterial, fungal, viral and parasitic analytes.

Moreover, while analyte determinations according to the preferred embodiment of this invention involve coupling the detectable reporter substance to analyte with the aid of stable association between the reporter substance and a lipid component of the analyte, this procedure has considerably broader applications. It should be understood, in this regard, that the same basic procedure may be applied in determinations of a wide range of analytes, using various other means to achieve reporter substance-analyte coupling, including chemical, physical or physico-chemical binding, e.g., covalent bonds, hydrogen bonds, polar attraction, van der Waals' attraction or adsorption, such as biospecific adsorption. Thus, it is contemplated that the methods described herein may be used for determination of substantially lipid-free analytes. Such methods are included within the scope of the present invention.

The present invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of considerable variation and modification without departure from the scope of the appended claims.

SUBSTITUTE SHEET

WHAT IS CLAIMED IS:

1. A method for determining the presence
or quantity of analyte, having a characteristic
5 determinant, in a test sample suspected of containing
said analyte, comprising:

(i) coupling a detectable reporter
substance with the analyte or with a specific binding
substance capable of interacting selectively with at
10 least one characteristic determinant of said analyte,
the analyte or specific binding substance to which the
reporter substance is coupled having a lipid
component, said reporter substance being stably
associated with said lipid component;

15 (ii) contacting said test sample with said
specific binding substance under conditions causing
complex formation between said analyte and said
specific binding substance;

20 (iii) separating said test sample into a
portion containing said complex and a portion
substantially free of said complex; and

(iv) detecting the occurrence of said
reporter substance in one of said separated portions
to provide an indication of the presence or quantity
25 of said analyte having said characteristic determinant
within said test sample.

2. A method according to claim 1, which
includes the step of relating the level of detected
reporter substance to a predetermined standard to
30 determine the presence or quantity of said analyte
within said test sample.

3. A method according to claim 2, wherein
the level of detected reporter substance is related to
a standard containing a predetermined quantity of
35 said reporter substance, thereby to quantitatively

SUBSTITUTE SHEET

determine the analyte having said characteristic determinant within said test sample.

5 4. A method according to claim 1, wherein said detectable reporter substance is coupled with said analyte.

 5. A method according to claim 4, wherein said analyte comprises biomembrane-containing entities selected from the group of eucaryotic cells, procaryotic cells and viruses.

10 6. A method according to claim 4, wherein the occurrence of said detectable reporter substance is detected in said complex-containing portion.

 7. A method according to claim 4, wherein said test sample is contacted with specific binding substance affixed to a solid phase.

15 8. A method according to claim 7, wherein the solid phase to which the specific binding substance is affixed comprises magnetic material, and said solid phase bearing said complex is magnetically separated from said complex-free portion.

20 9. A method according to claim 4, wherein said test sample is contacted with at least one antibody as the specific binding substance.

 10. A method according to claim 9, wherein the antibody contacted with said test sample is affixed to a solid phase.

25 11. A method according to claim 9, wherein the antibody contacted with said test sample is a monoclonal antibody.

30 12. A method according to claim 4, which includes contacting the test sample with a first specific binding substance capable of interacting selectively with at least one characteristic determinant of said analyte and a second specific binding substance capable of interacting selectively

35

SUBSTITUTE SHEET

with said first specific binding substance, said second specific binding substance being affixed to a solid phase.

5 13. A method according to claim 12, wherein said test sample is contacted with a first antibody as the first specific binding substance and with a second antibody as the second specific binding substance.

10 14. A method according to claim 4, wherein the level of detected reporter substance is related to a standard containing a predetermined quantity of membrane-bounded entities coupled to said reporter substance, thereby to quantitatively determine the analyte having said characteristic determinant within said test sample.

15 15. A method according to claim 4, wherein an extractable reporter substance is coupled to said analyte and said reporter substance is extracted therefrom prior to detection thereof.

20 16. A method according to claim 4, wherein the reporter substance coupled to said analyte is selected from the group consisting of molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable
25 by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties.

30 17. A method for analyzing a population of membrane-bounded cells to determine the presence or quantity of a subpopulation of cells expressing at least one characteristic antigen, within said population, comprising:

35 (i) coupling said cells to an extractable reporter substance, whereby said

SUBSTITUTE SHEET

extractable reporter substance is stably associated with the membrane of said cells;

(ii) contacting said cell population with antibodies capable of selectively interacting with said antigen, under conditions causing binding of said antibodies to said antigen, said antibodies being affixed to magnetic particles;

(iii) magnetically separating said magnetic particles bearing said subpopulation of cells from said population;

(iv) extracting said reporter substance from said separated subpopulation of cells; and

(v) detecting the level of extracted reporter substance in said separated subpopulation of cells, or in the population remaining after separation of said subpopulation to provide an indication of the presence or quantity of the subpopulation of cells expressing said characteristic antigen within said population.

18. A method according to claim 17, which includes the step of relating the level of detected reporter substance to a pre-determined standard to determine the presence or quantity of said subpopulation within said population.

19. A method according to claim 18, wherein the level of detected reporter substance is related to a standard containing a predetermined quantity of said reporter substance, thereby to determine the number of cells having said characteristic antigen within said population.

20. A method according to claim 17, wherein the reporter substance coupled to said cells is selected from the group consisting of molecules or ions directly or indirectly detectable based on light

SUBSTITUTE SHEET

absorbance, fluorescence, phosphorescence, or
luminescence properties; molecules or ions detectable
by their radioactive properties; and molecules or ions
detectable by their nuclear magnetic resonance or
paramagnetic properties.

21. A method according to claim 17, wherein
said cells are coupled to a fluorochrome as the
reporter substance.

22. A method according to claim 17, wherein
said population comprises cells selected from the
group of leukocytes, erythrocytes and mixtures
thereof.

23. A method according to claim 17, wherein
said population comprises hemopoietic cells and said
subpopulation of biological entities comprises
hemopoietic cells of a certain lineage, function or
stage of differentiation.

24. A method for analyzing a population of
membrane-bounded cells to determine the presence or
quantity of a subpopulation of cells expressing at
least one characteristic antigen, within said
population, comprising:

(i) coupling said cells to an
extractable reporter substance, whereby said
extractable reporter substance is stably associated
with the membrane of said cells;

(ii) contacting said cell population
with (a) antibodies which interact selectively with a
first characteristic determinant of said subpopulation
of biological entities and (b) specific binding
substance which interacts selectively with said
antibodies, said specific binding substance being
affixed to a solid phase;

(iii) separating from said population
the solid phase bearing said subpopulation of cells;

SUBSTITUTE SHEET

(iv) extracting said reporter substance from said separated subpopulation of cells;

(v) detecting the level of extracted reporter substance in said separated subpopulation of cells, or in the population remaining after separation of said subpopulation to provide an indication of the presence or quantity of the subpopulation of cells expressing said characteristic antigen within said population.

25. A method according to claim 24, which includes the step of relating the level of detected reporter substance to a pre-determined standard to determine the presence or quantity of said subpopulation within said population.

26. A method according to claim 25, wherein the level of detected reporter substance is related to a standard containing a predetermined quantity of membrane-bounded entities coupled to said reporter substance, thereby to determine the number of cells expressing said characteristic antigen within said population.

27. A method according to claim 24, wherein the reporter substance coupled to said cells is selected from the group consisting of molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties.

28. A method according to claim 24, wherein said cells are coupled to a fluorochrome as the reporter substance.

29. A method for analyzing a subpopulation of cells, having at least one characteristic

SUBSTITUTE SHEET

determinant, present within a population of cells,
said subpopulation of cells including individual
subsets of interest, each subset having at least one
characteristic determinant, to determine the
5 proportion of at least one subset of said cell
subpopulation, comprising:

(i) coupling substantially all of the
cells of said population, suspected of containing said
cell subpopulation, to a detectable reporter
10 substance, whereby said reporter substance is stably
associated with the membrane of said cells;

(ii) contacting a first sample of said
cell population with a first reagent comprising at
least one specific binding substance capable of
15 selectively interacting with a characteristic
determinant of said cell subpopulation, under
conditions causing binding of said first reagent to
cells of said subpopulation, thereby forming first
complexes in said first sample;

20 (iii) separating said first complexes
in said first sample from unbound cells in said first
sample;

(iv) detecting the occurrence of
reporter substance in said first complexes;

25 (v) contacting a second sample of
said cell population from step (i), of equivalent
volume and cell concentration to said first sample,
with a second reagent comprising a specific binding
substance capable of selectively interacting with a
30 characteristic determinant of a subset of interest,
under conditions causing binding of said second
reagent to said determinant, thereby forming second
complexes in said second sample;

35

SUBSTITUTE SHEET

(vi) separating said second complexes in said second sample from unbound cells in said second sample;

5 (vii) detecting the occurrence of reporter substance in said second complexes; and

(viii) determining the proportion of said subset of interest in said cell subpopulation by quantitating the amount of reporter substance associated with said second complexes relative to the amount of reporter substance associated with said first complexes.

10 30. A method according to claim 29, which includes:

(ix) contacting one or more additional samples of said cell population from step (i), each sample being of equivalent volume and cell concentration to said first sample, with additional reagent, each said additional reagent comprising a specific binding substance capable of selectively interacting with a characteristic determinant of an additional subset of interest, under conditions causing binding of each additional reagent to each said subset, thereby forming additional complexes in said additional samples;

25 (x) separating said additional complexes in each additional sample from unbound cells in each said additional sample.

(xi) detecting the occurrence of reporter substance in said additional complexes; and

30 (xii) determining the proportion of said additional subsets in said cell subpopulation by quantitating the amount of reporter substance associated with said additional complexes relative to the amount of reporter substance associated with said first complexes.

35

SUBSTITUTE SHEET

31. A method according to claim 29, wherein
said first reagent comprises a mixture of specific
binding substances, each said binding substance being
capable of binding to characteristic determinants of
individual subsets of interest comprising said
subpopulation, whereby substantially all cells of said
subpopulation are bound to said binding substances.

32. A method according to claim 29 or 30,
which includes the step of relating the level of
detected reporter substance to a predetermined
standard to determine the presence or quantity of said
subset within said subpopulation.

33. A method according to claim 32, wherein
the level of detected reporter substance in said
samples is related to a standard containing a
predetermined quantity of biomembrane containing
entities coupled to said reporter substance, thereby
to determine the number of cells in said samples.

34. A method according to claim 29 or 30,
wherein said first reagent, said second reagent and
said additional reagent contacted with said cell
samples comprise said specific binding substance bound
to a solid phase.

35. A method according to claim 29 or 30,
wherein said first reagent, said second reagent and
said additional reagent contacted with said cell
samples comprise said specific binding substance bound
to magnetic particles, and said first complexes, said
second complexes and said additional complexes bearing
said subpopulations of interest are magnetically
separated from said samples.

36. A method according to claim 29 or 30,
wherein said first reagent, said second reagent and
said additional reagent contacted with said cell

SUBSTITUTE SHEET

samples comprise at least one antibody as the specific binding substance.

5 37. A method according to claim 29 or 30, wherein said first reagent, said second reagent and said additional reagent contacted with said cell samples comprise at least one monoclonal antibody as the specific binding substance.

10 38. A method according to claim 29 or 30, wherein an extractable reporter substance is coupled to said cells and said reporter substance is extracted from said cells prior to detection thereof.

15 39. A method according to claim 29 or 30, wherein the reporter substance coupled to said analyte is selected from the group consisting of molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or
20 paramagnetic properties.

40. A method according to claim 29 or 30, wherein said detectable reporter substance coupled to said cells comprises a fluorochrome.

25 41. A method according to claim 29 which includes contacting said first sample with an auxiliary specific binding substance capable of interacting selectively with said first reagent, said auxiliary specific binding substance being affixed to a solid phase.

30 42. A method according to claim 29, which includes contacting said second sample with an auxiliary specific binding substance capable of interacting selectively with said second reagent, said auxiliary specific binding substance being affixed to
35 a solid phase.

SUBSTITUTE SHEET

43. A method according to claim 30, which includes contacting at least one of said additional samples with an auxiliary specific binding substance capable of interacting selectively with the additional reagent with which said additional sample is contacted, said auxiliary specific binding substance being affixed to a solid phase.

44. A method according to claims 41, 42 or 43, wherein said first sample, said second sample or said at least one additional sample are contacted with antibody as the auxiliary specific binding substance.

45. A method according to claim 44, wherein the antibody contacted with said first sample, said second sample and said at least one additional sample is monoclonal antibody.

46. A method for analyzing a population of membrane-bounded cells to determine the presence or quantity of a subpopulation of cells, expressing a characteristic determinant, within said population, comprising:

(i) coupling said cells to an extractable reporter substance, whereby said extractable reporter substance is stably associated with the membrane of said cells;

(ii) contacting said cell population with a specific binding substance capable of selectively interacting with said determinant under conditions causing binding of said specific binding substance to said determinant, said specific binding substance being affixed to a solid phase;

(iii) separating said solid phase, bearing said subpopulation, from said population;

(iv) extracting said reporter substance from said separated subpopulation of cells; and

SUBSTITUTE SHEET

(v) detecting the level of extracted reporter substance to provide an indication of the presence or quantity of the subpopulation of cells expressing said characteristic determinant within said population.

47. A method according to claim 46, which includes the step of relating the level of detected reporter substance to a pre-determined standard to determine the presence or quantity of said subpopulation within said population.

48. A method according to claim 47, wherein the level of detected reporter substance is related to a standard containing a predetermined quantity of membrane-bounded entities coupled to said reporter substance, thereby to determine the number of cells expressing said characteristic determinant within said population.

49. A method according to claim 46, wherein the reporter substance coupled to said analyte is selected from the group consisting of molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties.

50. A method according to claim 46, wherein said cells are coupled to an extractable fluorochrome as the reporter substance.

51. A method according to claim 46, wherein said subpopulation expresses a characteristic antigen and said cell population is contacted with an antibody to said antigen, as the specific binding substance.

52. A method according to claim 50, wherein the antibody contacted with said cell population is a monoclonal antibody.

5 53. A method according to claim 1, wherein said detectable reporter substance is coupled to said specific binding substance.

54. A method according to claim 53, wherein said analyte is immobilized on a solid phase, said solid phase is separated from said test sample and the
10 occurrence of said detectable reporter on said solid phase is determined.

55. A method according to claim 54, which includes the step of relating the level of detected reporter substance to a pre-determined standard to
15 determine the presence or quantity of said analyte in said test sample.

56. A method according to claim 54, wherein the reporter substance coupled to said analyte is selected from the group consisting of molecules or
20 ions directly or indirectly detectable based on light absorbance, fluorescence, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; and molecules or ions detectable by their nuclear magnetic resonance or
25 paramagnetic properties.

57. A method according to claim 54, wherein said specific binding substance is coupled to an fluorochrome as the detectable reporter moiety.

58. A method according to claim 57, wherein
30 said fluorochrome is extracted from said reagent prior to detection.

59. A method according to claim 54, which comprises determining the presence or quantity of multiple analytes in said test sample, each analyte
35 having a characteristic determinant, by contacting

SUBSTITUTE SHEET

5 said test sample with a different specific binding
substance for each individual analyte of said multiple
analytes to be determined, each said specific binding
substance interacting specifically with a
characteristic determinant of the individual analyte
in said test sample with which each said specific
binding agent is contacted, the specific binding agent
for each said individual analyte having a reporter
substance that is distinguishable from the reporter
10 substance of the other specific binding agents.

60. A method according to claim 59, wherein
the reporter substance of each specific binding
substance is a fluorochrome having distinct spectral
properties.

15 61. A reagent for determining analyte
having at least one characteristic determinant, said
reagent comprising a lipid-containing moiety, a
specific binding moiety capable of selective
interaction with said characteristic determinant, and
20 a detectable reporter moiety which is stably
associated with said lipid-containing moiety.

62. A reagent according to claim 61,
wherein said lipid-containing moiety and said specific
binding moiety of said reagent comprise a cell having
25 a naturally occurring receptor that selectively
interacts with the characteristic determinant of said
analyte.

63. A reagent according to claim 61,
wherein said lipid-containing moiety and said specific
binding moiety of said reagent comprise a cell having
30 an induced receptor that selectively interacts with
the characteristic determinant of said analyte.

64. A reagent according to claim 63,
wherein said cell is induced to express said receptor
35 by recombinant DNA technology.

SUBSTITUTE SHEET

65. A reagent according to claim 63,
wherein said cell is induced to express said receptor
by transfection.

5 66. A reagent according to claim 63,
wherein said cell is induced to express said receptor
by physiologic activation.

10 67. A reagent according to claim 61,
wherein said lipid-containing moiety and said specific
binding moiety of said reagent comprise a cell having
bound thereto an antibody or an antibody fragment that
selectively interacts with the characteristic
determinant of said analyte.

15 68. A reagent according to claim 67,
wherein a derivatized antibody or antibody fragment is
bound to the surface of said cell said derivatized
antibody or antibody fragment having a hydrocarbon
substituent which renders said derivatized antibody or
antibody fragment sufficiently non-polar as to have a
20 surface membrane retention coefficient of at least
about 90 during a 24 hour period in saline containing
up to 10 percent serum, the percent change in said
coefficient during said period being less than 10
percent.

25 69. A reagent according to claim 61,
wherein said reporter moiety is selected from the
group consisting of molecules or ions directly or
indirectly detectable based on light absorbance,
fluorescence, phosphorescence, or luminescence
properties; molecules or ions detectable by their
30 radioactive properties; and molecules or ions
detectable by their nuclear magnetic resonance or
paramagnetic properties.


35 70. A reagent according to claim 61,
wherein said reporter moiety is a luminescent
material.

SUBSTITUTE SHEET

71. A reagent according to claim 61,
wherein said reporter moiety is a light absorbing
material.

5 72. A reagent according to claim 61,
wherein said reporter moiety is a fluorochrome
selected from the group of cyanine, acridine,
pyridine, anthraquinone, coumarin, quinoline,
xanthene, phenoxazine, phenothiazine and hexatriene
dyes and derivatives thereof.

10 73. A reagent according to claim 61,
wherein said reporter moiety is a compound having the
formula:



20 wherein R and R₁ are the same or different and
represent substituents independently selected from the
group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or
aralkyl, the hydrocarbon chains of which having from 1
to 30 carbon atoms, and being linear or branched, said
25 substituents being unsubstituted or substituted with
one or more non-polar functional groups, one of R or
R₁ having at least 12 linear carbon atoms, and the sum
of the linear carbon atoms in R and R₁ being at least
23;

30 X and X₁ may be the same or different and
represent O, S, C(CH₃)₂ or Se;

Y represents a linking group selected from
-CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or
-CH=CH-CH=CH-CH=CH-CH=;


35

SUBSTITUTE SHEET

Z and Z₁ are the same or different and represent substituents selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, NHNH₂, NCS, NCO, SO₂NH₂, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

74. A reagent according to claim 61, wherein said reporter moiety is a compound having the formula:



wherein R and R₁ are the same or different and represent alkyl substituents, having from 1 to 30 carbon atoms, and being linear or branched, unsubstituted or substituted with halogen, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear atoms in R and R₁ being at least 23;

Z and Z₁ are the same or different and represent substituents selected from the group H, or lower alkyl having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

75. A reagent according to claim 61, wherein said reporter substance is 3,3'-di-n-octadecyloxocarbocyanine perchlorate.


76. A reagent according to claim 61,
wherein said reporter substance is
3-n-Pentyl-3'-n-octadecyloxacarbocyanine Iodide.

77. A reagent according to claim 61,
wherein said reporter substance is
3-n-Octyl-3'-n-octadecyloxacarbocyanine Iodide.

78. A reagent according to claim 61,
wherein said reporter substance is
3-n-Propyl-3'-n-eicosanyloxacarbocyanine Iodide.

79. A reagent according to claim 61,
wherein said reporter substance is
3-n-Propyl-3'-n-docosanyloxacarbocyanine Iodide.

80. A reagent according to claim 61,
wherein said reporter substance is a compound having
the formula:



wherein R and R₁ are the same or different and
represent alkyl substituents, having from 1 to 30
carbon atoms, and being linear or branched,
unsubstituted or substituted with halogen, one of R or
R₁ having at least 12 linear carbon atoms and the sum
of the linear atoms in R and R₁ being at least 23;

Z and Z₁ are the same or different and
represent substituents selected from the group H, or
lower alkyl having from 1 to 3 carbon atoms; and

A represents a biologically compatible
anion.

81. A reagent as claimed in claim 61,
wherein said reporter substance is 1,1'-di-n-


octadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate.

82. A reagent as claimed in claim 61, wherein said reporter substance is 1-n-octadecyl-1'-n-pentyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate.

83. A reagent as claimed in claim 61, wherein said reporter substance is 1-n-docosanyl-1'-n-propyl-3,3,3',3'-tetramethylindocarbocyanine iodide.

84. A reagent as claimed in claim 61, wherein said reporter substance is 2-[3-(1-n-docosanyl-benzoxazol-2-yliden)-1-propenyl]-6-iodo-1-n-tetradecyl-benzothiazolium iodide.

85. A reagent according to claim 61, wherein said reporter substance is a compound having the formula:



wherein R represents a substituent selected from the group of alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chain of which is linear or branched, said substituent being unsubstituted or substituted with one or more non-polar functional groups, and having at least 23 linear carbon atoms;

Z, Z₁ and Z₂ are the same or different and represent substituents selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, -NHNH₂, -NCS, -NCO, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, N(alkyl)₂, SH, S-alkyl, NO₂, or

SUBSTITUTE SHEET

halogen, the alkyl groups comprising said Z
substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible
anion.

5 86. A reagent according to claim 61,
wherein said reporter substance is 3,6-bis-
(dimethylamino)-10-n-hexacosanyl acridinium iodide.

87. A reagent according to claim 61,
wherein said reporter substance is 4-[4-didecylamino-
10 styryl]-N-methylpyridinium iodide.

88. A reagent according to claim 61,
wherein said reporter substance is N-[3-Sulfopropyl]-
4-[p-didecylaminostyryl] pyridinium, inner salt.

89. A reagent according to claim 61,
15 wherein said specific binding moiety comprises at
least one antibody.

90. A reagent according to claim 89,
wherein said antibody is monoclonal antibody.

91. A reagent according to claim 89,
20 wherein said antibody interacts selectively with
determinants of procaryotic cells, eucaryotic cells or
viruses.

92. A reagent according to claim 91,
wherein said antibody is monoclonal antibody.

93. A reagent according to claim 89,
25 wherein said specific binding substance comprises at
least one antibody fragment.

94. A test kit for determining analyte
in a test sample, said analyte having a lipid
30 component and at least one characteristic determinant,
said test kit comprising:

(i) a detectable reporter substance
for coupling to said analyte, said reporter substance
being capable of stable association with said lipid
35 component; and

SUBSTITUTE SHEET

(ii) a reagent comprising at least one specific binding substance capable of selective interaction with at least one characteristic determinant of said analyte.

5 95. A test kit according to claim 94, which includes medium for coupling said reporter substance to said analyte.

10 96. A test kit according to claim 94, wherein said specific binding substance is affixed to a solid phase.

 97. A test kit according to claim 96, wherein said solid phase comprises magnetic material.

 98. A test kit according to claim 96, wherein said specific binding substance is antibody.

15 99. A test kit according to claim 98, wherein said antibody is monoclonal antibody.

 100. A test kit according to claim 97, wherein said specific binding substance is antibody.

20 101. A test kit according to claim 100, wherein said antibody is monoclonal antibody.

 102. A test kit according to claim 94, which includes an extractant for extracting said reporter substance from said analyte.

25 103. A test kit according to claim 94, which includes at least one pre-determined standard for determining the presence or quantity of said analyte in said test sample. .

30 104. A test kit according to claim 103, wherein said standard comprises membrane-bounded entities stably associated with said reporter substance.

35 105. A test kit according to claim 94, which includes instructions for preparation of a standard for determining the presence or quantity of said analyte in said test sample.


SUBSTITUTE SHEET

106. A test kit according to claim 94,
wherein said reporter substance is a luminescent
material.

107. A test kit according to claim 94,
wherein said reporter substance is a light absorbing
material.

108. A test kit according to claim 94,
wherein said reporter substance is a fluorochrome
selected from the group of cyanine, acridine,
pyridine, anthraquinone, coumarin, quinoline,
xanthene, phenoxazine, phenothiazine and hexatriene
dyes and derivatives thereof.

109. A test kit according to claim 94,
wherein said reporter substance is a compound having
the formula:



wherein R and R₁ are the same or different and
represent substituents independently selected from the
group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or
aralkyl, the hydrocarbon chains of which having from 1
to 30 carbon atoms, and being linear or branched, said
substituents being unsubstituted or substituted with
one or more non-polar functional groups;

X and X₁ may be the same or different and
represent O, S, C(CH₃)₂ or Se;

Y represents a linking group selected from
-CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or
-CH=CH-CH=CH-CH=CH-CH=;

Z and Z₁ are the same or different and represent substituents selected from the group H alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, NHNH₂, NCS, NCO, SO₂NH₂, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

110. A test kit for analyzing a subpopulation of biomembrane-containing entities, having at least one characteristic determinant, present within a population of said entities, said subpopulation including individual subsets of biomembrane-containing entities of interest, each said subset having at least one characteristic determinant, to determine the proportion of at least one subset in said subpopulation, said kit including (i) a detectable reporter substance for coupling to the population of biomembrane-containing entities, said reporter substance being capable of stable association with the lipid component of said biomembrane; (ii) a first reagent comprising at least one specific binding substance capable of selective interaction with at least one characteristic determinant of said subpopulation; and (iii) at least one additional reagent comprising at least one specific binding substance capable of selective interaction with at least one characteristic determinant of at least one subset of said subpopulation.

111. A test kit according to claim 110, which includes at least one predetermined standard for quantitating complex formation between said first reagent and said subpopulation and between said at

SUBSTITUTE SHEET

least one additional reagent and the subset with which said at least one additional reagent forms complexes.


112. A test kit for determining analyte in a test sample, said analyte having a characteristic determinant, said test kit including a reagent comprising a lipid-containing moiety, a specific binding moiety capable of selective interaction with said characteristic determinant and a detectable reporter moiety which is stably associated with said lipid-containing moiety.

113. A test kit according to claim 112, wherein said reporter moiety is a luminescent material.

114. A reagent according to claim 112, wherein said reporter moiety is a light absorbing material.

115. A test kit according to claim 112, wherein said reporter moiety is a fluorochrome selected from the group of cyanine, acridine, pyridine, anthraquinone, coumarin, quinoline, xanthene, phenoxazine, phenothiazine and hexatriene dyes and derivatives thereof.

116. A test kit according to claim 111, wherein said reporter moiety is a compound having the formula:



wherein R and R₁ are the same or different and represent substituents independently selected from the group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which having from 1 to 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R₁ having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R₁ being at least 23;

X and X₁ may be the same or different and represent O, S, C(CH₃)₂ or Se;

Y represents a linking group selected from -CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or -CH=CH-CH=CH-CH=CH-CH=;

Z and Z₁ are the same or different and represent substituents selected from the group H alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, NHNH₂, NCS, NCO, SO₂NH₂, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

117. A test kit according to claim 112, which further includes a solid phase for immobilizing said analyte.

118. A test kit according to claim 112, which further includes an extractant for extracting said reporter substance from said entities.

119. A test kit according to claim 112, which further includes a pre-determined standard for determining the presence or quantity of said analyte in said test sample.

SUBSTITUTE SHEET

120. A test kit according to claim 112,
which further includes instructions for preparation of
a standard for determining the presence or quantity of
said analyte in said test sample.

5 121. A method according to claim 1, wherein
said detectable reporter substance is coupled to said
specific binding substance and the step of contacting
said test sample with said specific binding substance
includes adding to said test sample a known quantity
10 of the analyte to be determined, thereby to effect
competition between any analyte originally present in
the test sample and the added analyte for complex
formation with said specific binding substance.

122. A method for determining the presence
15 or quantity of a subpopulation of biological entities,
having at least one characteristic determinant, within
a population of said entities, comprising:

(i) coupling a detectable reporter
substance to said biological entities;

20 (ii) contacting said biological
entities with a specific binding substance capable of
interacting selectively with at least one
characteristic determinant of said subpopulation of
biological entities, under conditions causing binding
25 of said binding substance to said at least one
determinant;

(iii) separating said binding
substance, bearing said subpopulation of biological
entities, from said population; and

30 (iv) detecting the occurrence of said
detectable reporter substance in said separated
subpopulation of biological entities or in the
population remaining after separation of said
subpopulation to provide an indication of the presence
35 or quantity of the subpopulation of biological



SUBSTITUTE SHEET

entities having said characteristic determinant within said population.

123. A method according to claim 122, which includes the step of relating the level of detected reporter substance to a predetermined standard to determine the presence or quantity of said subpopulation within said population.

124. A method according to claim 122, wherein the level of detected reporter substance is related to a standard containing a predetermined quantity of said reporter substance, thereby to determine the number of biological entities having said characteristic determinant within said population.

SUBSTITUTE SHEET

**FIG. 1****FIG. 2**

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/02341

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC U.S. CL.: 435/5,7,29; 436/501,504,526,538,544,545,546,71,172,173,800,829; see attach. IPC(5):C12Q 1/02,70 ; C09H 1/04; A01N 5/26,28; A61K 35/14; see attachment.		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S. CL.:	435/5,7,29; 436/501,503,504,518,519,526,536,538,544,545,546, 71,172,173,800,829; 424/9,11, 417, 450, 86, 87; 530/359, 380, 387, 808	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁴
A, P	US, A, 4,876,189,(SCHEPERS) et al., 24 October 1989, see Abstract and column 2, line 17- column 3, line 2.	1-3,53-57 & 121
A	US, A, 4,806,488,(BERGER, JR. et al.) 21 February 1989, see column 2, lines 35-68, column 4, lines 12-28 and 44-67, column 5, lines 20-49, column 6, lines 3-31, column 12, line 37- column 13, line 32, column 15, lines 11-17 and claims 76-82.	1,4-7,9-14, 16, 53-57,61, 69,70,72,89, 91,94,96,110, 112,115 and 121
A Y	US, A, 4,783,401(HORAN, et al) 08 November 1988, see Abstract, column 1, lines 28-39, column 2, lines 59-66, column 3, lines 8- 29, column 4, lines 10-16 and column 7, lines 56-59.	1-60,121-124 61-88,94-95, 110, 112-116
A Y	US, A, 4,751,188,(VALET) 14 June 1988, see column 1, line 43- column 2, line 27.	1-60,121-124 61-88,94-95, 103-104,106- 116, 120
<p>¹⁵ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
28 August 1990	10 OCT 1990	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	Janette Graeter	

PCT/US90/02341

Attachment to PCT/ISA/210

I. Classification of Subject Matter:

U.S. CL.: 530/359, 380, 387, 808; 424/11, 417, 450

IPC (5): A61K 37/04,22; G01N 33/48,53, 92, 532, 533, 534, 537;
555, 566, 567

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, * with indication, where appropriate, of the relevant passages **	Relevant to Claim No. 1*
<u>A</u> Y	US, A, 4,727,020,(RECKTENWALD) 23 February 1988, see Abstract, column 2, lines 24-49 and 61-68, column 3, lines 1-61, column 4, line 9- column 5, line 40, column 5, line 54- column 6, line 16.	1-14,16,24-28,46-52,94-95,106-110,121-124 29-45
A	US, A, 4,717,655,(FULWYLER) 05 January 1988, see Abstract and column 1, line 67- column 2, line 28.	29-45
Y	US, A, 4,708,933,(HUANG et al.) 24 November 1987, see Abstract and column 2, lines 30-33.	61,69-90
A	US, A, 4,649,106,(SCHLOSSMAN et al.) 10 March 1987, see Abstract and column 1, line 53- column 2, line 9.	17-28
<u>X</u> Y	EP, A, 0 248 621,(HATOH et al.) 09 December 1987, see Abstract and claims 1, 10 and 11.	61,69-72,89 73-80,86-88, 90,93
X	JP, A, 61-269070,(NISSUI SEIYAKU KK) 28 November 1986, see English Abstract.	61,69,89,90
<u>X</u> Y	EP, A, 0 176 252,(CHANG et al.) 02 April 1986, see Abstract, page 3, lines 5-9, page 4, lines 16-34, page 8, lines 1-19, page 9, line 34- page 10, line 4, page 10, line 20- page 11, line 15 and page 12, line 12- page 13, line 7.	61-62,67,69-72,89,91,94, 110,112-115 63-66,73-80, 86-88,90,92-93,96-109,111, 113-120